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Abstract
Rationale: Observational data on antiepileptic drugs (AEDs) inform about their use in clinical
practice. We describe our clinical experience with perampanel (PER) in a large UK tertiary
epilepsy center.
Methods: Adults initiated on PER between October 2012 and March 2015 were followed until
they discontinued PER or 10 September 2016. Data on epilepsy syndrome, duration, seizure
types, concomitant and previous AED use, PER dosing, efficacy and side effects were recorded.
Efficacy was categorized as temporary or ongoing (at last follow up) seizure freedom, ≥50% 
seizure reduction, or other benefit (e. g. No convulsions or daytime seizures). These categories
were mutually exclusive except for people with temporary seizure freedom.
Results: 391 received a PER prescription, five of whom never took it. No follow up data were
available for ten. 83% had focal epilepsy. People were prescribed PER in addition to 1-7
(Interquartile range [IQR] 2, 2, 3) AEDs and had previously used up to 18 (IQR 5, 7, 10) AEDs.
Total exposure was 639 patient/years. Retention rates were 60.4% at one year, 48.3% at two
years, and 42.7% at three years. 19 (5%) people reported seizure free periods lasting at least six
months. A ≥50% reduction in seizures lasting at least six month was reported by 76 people 
(20%), and marked improvement for ≥6 months was seen in 52 (14%). Five (1%) were taken off 
other AEDs and continued onPER monotherapy for 4 – 27 months. Seizures aggravated in 57
(15%). Somatic side effects were reported by 197 (52%), mostly CNS. Mood changes, irritability
or challenging behaviour were reported by 137 (36%). PER was discontinued by 211 (56%) due
to adverse effects (39%), inefficacy (26%), or both (35%). No idiosyncratic adverse events were
seen. .
Conclusion: PER resulted in some benefit in 40% of those exposed. Adverse effects on mental
health and on balance were common and should be discussed with people before initiating PER.
Highlights:
 Single center observation of 376 adults with epilepsy treated with perampanel
 Perampanel retention was 60% at one year, 48% at 2 years, 43% at 3 years
 73% reported adverse effects, largely affecting the CNS (52%) or mental health (36%).
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1. Introduction1
PER is a recently introduced AED which acts as a non-competitive antagonist at AMPA
receptors in the brain, so reducing neuronal excitability.[1] PER was licensed as add-on
treatment in focal epilepsy following results from three randomised controlled trials in people
with pharmacoresistant epilepsy. [2][3][4]
Regulatory trials establish whether an AED is effective, but do not inform about its use in “real-
life” population with epilepsy, many of whom might not meet the inclusion criteria for these
trials for a number of reasons. We have evaluated the use of newly introduced AEDs over the
past 20 years.[5][6][7][8][9][10] Here, we present a similar observation on the use of PER.
1 Abbreviations:
AED – antiepileptic drug
IQR – interquartile range
PER – perampanel
SD – standard deviation
SUDEP – sudden unexplained death in epilepsy
2. Patients and Methods
Adults 17 years and older with epilepsy who received their first prescription for PER at the
epilepsy specialist clinics at National Hospital for Neurology and Neurosurgery (Queen Square
and Chalfont sites) between 1 October 2012 and 31 March 2015 were identified using the
hospital’s central pharmacy database and the departmental database. People started on PER
elsewhere were excluded to avoid referral bias. Data regarding epilepsy syndrome, seizure
types, age at onset of epilepsy, psychiatric comorbidity (if listed in records or inferred by use of
antidepressant or antipsychotic medications), presence of learning disability, and use of current
and previous AEDs, date of starting and stopping (where applicable) PER, maximum attained
dose and maintenance dose were extracted from records. All started PER as add-on treatment.
The starting dose was 2 mg per day and was typically increased every two to four weeks by 2 mg
as tolerated. At our center, people with epilepsy are typically seen every six months, though they
are encouraged to make phone contact in between if needed. All encounters with epilepsy care
providers were analyzed to assess effect on seizure frequency and severity, adverse effects, and
reasons to discontinue PER where applicable. Effect on seizures was categorized as seizure
freedom for >5 times the average interval in between seizures during the previous year, a
reduction in seizures by 50% or more, any other marked improvement in the assessment of either
the individual or the physician, or worsening of seizures. Examples of marked improvement
were cessation of convulsions, significant shortening of seizure or postictal confusion duration or
reduction in seizure related falls or injuries. These categories were mutually exclusive except for
periods of temporary seizure freedom (i. e. a person who reported initial seizure freedom of six
months, followed by >50% reduction in seizure freedom for 12 months, appeared in both
categories). We only considered beneficial effects lasting six months or longer in the analysis to
avoid the regression to mean phenomenon.[11] Seizure aggravation was noted if there was a
significant increase in seizure frequency or seizure related morbidity. People were followed until
they discontinued PER; data were censored on 10 September 2016 for those continuing on PER.
Current AED use was assessed on the day of starting PER; i. e. changes in AEDs other than PER
were not captured. Three people underwent temporal lobe resections after starting PER.
Improvement following surgery was not attributed to PER. This exercise was approved as an
audit, and no ethics approval was necessary.
Data were collected in a Microsoft Excel Spreadsheet. Statistical analysis was performed using
SPSS 16 (SPSS Inc, Chicago, IL) using descriptive statistics, Fisher’s exact test, Mann-Whitney
tests, Kaplan-Meier Survival analysis, and Cox regression analysis as indicated in the
manuscript.
3. Results
3.1. Baseline characteristics and dosing
391 people received a prescription for PER between 22 October 2012 and 31 March 2015. For
five, there was no subsequent evidence that they ever took the drug. No follow up data were
available for ten people. The analysis thus includes 376 adults who took PER for a period of 4 –
1389 days (censored), a total of 639 patient-years exposure. Demographic variables are given in
table 1. People were prescribed PER in addition to 1-7 (IQR 2, 2, 3) AEDs and had documented
use of 1-18 (IQR 5, 7, 10) further AEDs. Table 2 lists AEDs used in addition to PER in at least
5% of people.
Tables 1, 2 and 3 about here
The maximum attained dose of PER was 2 - 16 mg (IQR 4, 8, 10) mg in all people, and 1 - 14
(IQR 6, 8, 10) mg in those who continued the drug at last follow up (table 3). Men attained a
higher maximum dose than women, and people on at least one enzyme-inducing AED
(carbamazepine, phenytoin, phenobarbitone, primidone, topiramate) at the time of PER initiation
attained a higher maximum dose of PER compared to those on no enzyme-inducing AEDs.
Those who reported side effects attained lower maximum doses than those who did not.
3.2. Benefits of perampanel
19 people (5%) reported periods of seizure freedom lasting 6 months or more. This benefit was
temporary for up to 19 (median 9) months in ten, and ongoing at last follow up for up to 38 (18)
months in nine. A reduction in seizure frequency by >50% for 6 months or longer was seen in
76 (20%), temporary for up to 36 (17) months in 31 and ongoing at last follow up for up to 42
(28) months in 45. A marked improvement for a minimum of 6 months was noted by 52 people
(14%), temporary for up to 33 (12) months in 12 and ongoing at last follow up for up to 41 (24)
months in 40. 57 people (15%) reported seizure aggravation resulting in discontinuation of PER
in most cases and significant reduction of the dose in the remaining. Five people discontinued
other AEDs and converted to PER monotherapy. People who reported periods of seizure
freedom lasting six months or more had failed fewer AEDs (mean 7.4, median 6, range 1-13)
than those who did not report this benefit (mean 10.1, median 10, range 2-21, p=0.003). There
were no differences in the number of previously failed AEDs for the subgroups who reported
seizure reduction by 50% or more for six months or longer, or those who reported “marked
improvement” for six months or longer, versus those who did not.
3.3. Adverse events on perampanel
197 people (52%) reported side effects, largely drowsiness, dizziness, and unsteadiness. A
negative effect on mental health (worsening of mood, increased irritability, or challenging
behavior was observed in 137 (36%). One man required hospitalization for a psychotic episode
shortly after starting PER. One man got arrested and another one cautioned for aggressive
behavior. No idiosyncratic side effect was seen. There were two deaths in the cohort, one from
myocardial infarction, one from complications of longstanding pulmonary hypertension. Neither
case was attributed to PER. No cases of SUDEP were observed.
3.4. Retention and Cox regression analysis
Estimated retention of PER was 60.4% (95% CI 55.4 – 65.3%) at one year, 48.3% (43.2 –
53.3%) at two years, and 42.7% (37.5 – 48%) at three years (figure). As of 10 September 2016,
211 people (56%) have discontinued PER due to side effects (82, 39%), inefficacy or worsening
of seizures (55, 26%), or both (74, 35%). Univariate Cox regression analysis (table 4) suggests a
significant (p<0.05) positive association with PER retention for concomitant use of pregabalin,
maximum attained dose, periods of seizure freedom, 50% seizure reduction, or other significant
improvement. Psychiatric side effects (most commonly irritability (n=81) and depression
(n=41)), and seizure aggravation were negatively associated with PER retention. Age at epilepsy
onset, age at starting PER, epilepsy syndrome, presence of psychiatric comorbidity or learning
disability, number of concomitant AEDs and number of failed AEDs did not affect retention.
We then performed a stepwise multivariate backwards regression analysis including all
parameters that had been found to have an association (positive or negative) with PER retention
at a level of p<0.2 (table 5). Concomitant use of pregabalin and maximum attained dose
remained positively associated with PER retention, as did periods of benefits as described above.
Worsening of seizures, presence of psychiatric or somatic side effects and concomitant use of
zonisamide were negatively associated with PER retention at a significance of p<0.05.
Figure, Table 4 and 5 about here
There were no differences in the number of people who reported somatic or psychiatric side
effects when comparing the subgroups who were on concomitant pregabalin or zonisamide when
starting PER with those who were not on these AEDs. There were also no differences in the
continuing or maximum dose attained in those on concomitant pregabalin or zonisamide versus
those not on these AEDs.
4. Discussion
4.1. Comparison to regulatory trials and other retention reports
A temporary or ongoing benefit lasting at least six months was reported by nearly 40% of people
following the introduction of PER. These results are comparable to the efficacy reported in the
regulatory trials (studies 304-306) [2][3][4], though inferior to the results of an open label
extension study reporting seizure reduction of up to 58% in people who took PER for two
years.[12] This difference may be attributed to the fact that three quarters of people in our cohort
had failed at least seven AEDs prior to commencing PER. Side effects in this cohort were
similar to those reported previously in regulatory trials. No idiosyncratic side effects emerged.
This is similar to previous reports. [13][14] No cases of SUDEP were observed in these 639
patients/years of exposure. The estimated incidence of SUDEP is ~1 in 200 people with
refractory epilepsy per year.[15] We thus would have expected at least one case of SUDEP
during this period but numbers are small.
Retention rates at one, two and three years in this cohort were similar to those observed in our
historical cohort of people on lacosamide at one (60% for PER vs 62% for lacosamide) and two
years (48% vs 45%), and slightly better at three years (43% vs 35%).[9] While these two cohorts
were similar in regards to their demographic characteristics, people in the PER cohort had failed
one more AED (median) than those in the lacosamide cohort.
Prior observational studies on PER use have reported 12 months retention rates of 46 – 60.6%
[16][17][18][19][20], with broadly similar rates and types of side effects.
During enrolment, PER was licensed as add-on treatment for focal seizures only. The drug was
used “off- label” in 17% of the cohort at the discretion of the prescribing physician. In June
2015, the indication for PER was expanded to add-on in primary generalized tonic clonic
seizures.
There were no differences in PER retention or attained doses of PER for people age 60 years or
older compared to those younger than 60 years, in line with the findings of a post-hoc analysis of
people age 65 and above in the PER regulatory trials.[21]
Adverse effects on mental health were reported by more than one third of people in line previous
reports.[17][19] We did not systematically collect data with regards to specific side effects that
lead to discontinuation. Psychiatric side effects judged to be severe in this cohort were observed
in three. The possibility of these side effects should be discussed with individuals and PER
should be used cautiously in people with a history of aggressive behavior.
PER retention was positively affected by concomitant use of pregabalin and negatively by
zonisamide. There were no differences in the presence of somatic or psychiatric adverse effects,
and no differences in the doses attained in those who took PER with or without combination with
pregabalin or zonisamide. No pharmacodynamic or pharmacokinetic interaction between
pregabalin and PER or zonisamide and PER have been yet described.[1][22] The observed
effects of concomitant use of certain AEDs on PER retention might be a statistical artefact, the
potential beneficial effect of pregabalin was the factor with the strongest modifiable effect in
both univariate and multivariate Cox regression analysis. We therefore believe that this potential
association deserves further investigation.
From a practical standpoint, our data suggest that a substantial minority of people with
pharmacoresistant epilepsy experience some form of benefit from PER, despite having failed
many AEDs. Further observations are warranted to determine whether PER might be more
beneficial in people who have failed fewer AEDs. Adverse effects on mental health are the most
relevant in clinical practice. These should be thoroughly discussed with individuals and actively
explored after starting PER.
.
4.2. Limitations
There are a number of limitations: PER effects were not prospectively assessed but
retrospectively collected and may thus be subject to recall and reporting bias. We relied on data
that were not systematically captured during routine clinical encounters and documented in
medical records only. The documented use of previous AEDs therefore may have
underestimated the actual use, in particular in those who had apparently failed only few AEDs
prior to PER. These effects were, however, judged to be small and thus unlikely to affect the
analysis on retention. Seizure counts have been shown to be inaccurate [23], and no systematic
use of seizure diaries was ensured. Beneficial effects in few individuals may have been falsely
attributed to PER in the presence of another intervention (e. g. further subsequent drug change in
rare cases), though we did not attribute benefits that appeared after resective epilepsy surgery.
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Gender (female) 219 58%
Age when starting PER (years) 32, 42, 50 (IQR) 17-82 (range)
Age at epilepsy onset (years) 5, 12, 19 (IQR) first year of life – 79
Psychiatric history 101 27%
Learning disability 68 18%
Focal epilepsy 314 83%
Symptomatic 193 51%
Cryptogenic 121 32%
Generalised epilepsy 58 16%
Symptomatic 26 7%
Cryptogenic 25 7%
Idiopathic 7 2%
Unclassified 4 1%
Number of AEDs previously tried
(excluding current AEDs) with
evidence in electronic medical records
7 (median) 0-18 (range)
Number of AEDs previously tried
(including current AEDs) 10 (median) 1-21 (range)
Number of concomitant AEDs
One 52 14%
Two 137 36%
three 121 32%
Four or more 66 18%
Table 1: Demographic characteristics of people in the cohort.
Antiepileptic drug N %
Carbamazepine 143 38
Levetiracetam 133 35
Clobazam 117 31
Lamotrigine 85 23
Lacosamide 75 20
Zonisamide 65 17
Sodium Valproate 64 17
Oxcarbazepine 62 17
Phenytoin 42 11
Topiramate 41 11
Pregabalin 32 9
Clonazepam 22 6
Phenobarbitone 19 5
Table 2: Antiepileptic drugs used at time of initiating perampanel in at least 5% of the cohort
Maximum dose (mg)
(number of people)
Continuing dose (mg)
(number of people)
All people 7.3 ± 3.1 (376) p-value2 7.5 ± 3.3
(165)
p-value2
Men 7.9 ± 3.0 (157) 7.8 ± 3.1 (75)
Women 6.9 ± 3.1 (219) 0.001 7.3 ± 3.4 (90) 0.411
People on ≥ 1 enzyme inducing AED1 7.6 ± 3.1 (214) 8.1 ± 3.1 (101)
People on no enzyme inducing AED1 6.9 ± 2.9 (162) 0.029 6.7 ± 3.3 (64) 0.007
People <60 years old1 7.4 ± 3.1 (342) 7.7 ± 3.3 (151)
People ≥60 years old1 6.3 ± 2.8 (34) 0.083 6.3 ± 3.1 (14) 0.143
People who reported adverse effects 7.0 ± 2.9 (276) 7.0 ± 3.2 (105)
People who did not report adverse effects 8.1 ± 3.3 (100) 0.003 8.4 ± 3.3 (60) 0.011
People with somatic adverse effects 6.9 ± 2.9 (197) 7.1 ± 3.2 (82)
People without somatic adverse effects 7.7 ± 3.2 (179) 0.032 8.0 ± 3.4 (83) 0.093
People with psychiatric adverse effects 6.9 ± 2.7 (137) 6.4 ± 3.1 (45)
People without psychiatric adverse
effects
7.5 ± 3.2 (239) 0.055 7.9 ± 3.3 (120) 0.008
SD, standard deviation
1 at time of starting perampanel
2 two-tailed Mann Whitney test, uncorrected for multiple comparisons
Table 3: Maximum and continuing doses of PER attained in subgroups
Factors positively associated with perampanel retention
Odds Ratio1 95.0% CI1 p-value
Concomitant use of pregabalin (n=32) 0.39 0.20 -0.76 0.006
Concomitant use of oxcarbazepine (n=62) 0.75 0.51- 1.10 0.144
Presence of simple partial seizures (n=179) 0.77 0.59 - 1.01 0.057
Maximum dose attained 0.80 0.76 - 0.84 <0.001
Male gender (n=157) 0.80 0.61 - 1.06 0.115
Duration of seizure freedom (n=19) 0.88 0.80 - 0.96 0.005
Number of concomitant AEDs used 0.89 0.78 - 1.01 0.078
Duration of marked improvement (n=52) 0.89 0.85 - 0.94 <0.001
Duration of >50% improvement of seizure
frequency (n=76) 0.93 0.91 - 0.96 <0.001
Factors negatively associated with perampanel retention
Odds ratio1 95% CI1 p-value
Worsening of seizures (n=56) 2.75 1.99 - 3.79 <0.001
Concomitant use of gabapentin (n=8) 2.10 0.99 - 4.47 0.054
Presence of psychiatric side effects (n=137) 1.55 1.18 - 2.04 0.002
Previous use of retigabine (n=96) 1.43 1.06 - 1.91 0.018
Previous use of oxcarbazepine (n=104) 1.36 1.02 - 1.82 0.039
Concomitant use of zonisamide (n=65) 1.30 0.93 - 1.82 0.126
Previous use of lacosamide (n=201) 1.26 0.96 - 1.66 0.095
Presence of somatic side effects (n=197) 1.20 0.91 - 1.57 0.195
Number of previous AEDs used 1.02 0.99 - 1.06 0.183
1 Odds ratio and 95% confidence interval of the probability of discontinuing perampanel.
Table 4: Results of univariate Cox regression analysis. Only factors with a p-value of <0.2 are
listed.
Factors positively associated with perampanel retention
Odds Ratio1 95% CI1 p-value
Concomitant use of pregabalin (n=32) 0.49 0.25 - 0.96 0.038
Maximum dose attained 0.78 0.73 - 0.82 <0.001
Duration of marked improvement (n=52) 0.88 0.84 - 0.93 <0.001
Duration of seizure freedom (n=19) 0.89 0.83 - 0.96 0.003
Duration of >50% improvement of seizure
frequency (n=76) 0.92 0.90 - 0.95 <0.001
Factors negatively associated with perampanel retention
Odds Ratio1 95% CI1 p-value
Worsening of seizures (n=56) 2.33 1.65 - 3.30 <0.001
Presence of psychiatric side effects (n=137) 1.78 1.34 - 2.38 <0.001
Concomitant use of zonisamide (n=65) 1.53 1.09 - 2.16 0.015
Previous use of lacosamide (n=201) 1.49 1.12 - 1.98 0.006
Presence of somatic side effects (n=197) 1.49 1.13 - 1.96 0.005
Previous use of oxcarbazepine (n=104) 1.36 1.01 - 1.84 0.043
1 Odds ratio and 95% confidence interval of the probability of discontinuing perampanel.
Table 5: Results of multivariate Cox regression analysis. All factors listed in table 4 were
included in a stepwise backword logistic regression analysis until only factors with a p-value
<0.05 remained.
Figure: retention of perampanel
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